Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Cash & Equivalents (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Cash & Equivalents for 16 consecutive years, with $10.4 million as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents rose 57.67% to $10.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Sep 2025, up 57.67% year-over-year, with the annual reading at $6.2 million for FY2024, 8.47% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $10.4 million at Xtant Medical Holdings, up from $6.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $20.3 million in Q2 2021, with the low at $4.1 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $11.3 million, with a median of $8.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 679.28% in 2021, then plummeted 74.91% in 2023.
  • Over 5 years, Cash & Equivalents stood at $18.2 million in 2021, then rose by 11.26% to $20.3 million in 2022, then tumbled by 71.84% to $5.7 million in 2023, then rose by 8.47% to $6.2 million in 2024, then soared by 67.77% to $10.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $10.4 million, $6.9 million, and $5.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.